Table 12:

Event Rates, Treatment Effects, and Severity: Major Bleeds

Baseline Risk of Major Bleeds
HAS-BLED Score	Annual Probability of Event	Standard Error	Source
0	0.000	0.0074a	Friberg et al, 201250
1	0.011	0.0074	Friberg et al, 201250
2	0.021	0.0077	Friberg et al, 201250
3	0.031	0.0011	Friberg et al, 201250
4	0.047	0.0023	Friberg et al, 201250
5	0.070	0.0077	Friberg et al, 201250
6	0.145	0.0408	Friberg et al, 201250
7	0.228	0.2575	Friberg et al, 201250
Treatment Effects
Intervention:Comparator	Odds Ratio	Standard Error	Source
Warfarin:aspirin	1.90	0.2942	Aguilar et al, 200753
LAAC device:warfarin	0.95	0.2011	FDA, 201555
Apixaban: warfarin	0.69	0.0738	ARISTOTLE, Granger et al, 201116
Dabigatran 110 mg:warfarin	0.80	0.0773	RE-LY, Connolly et al, 200915
Dabigatran 150 mg:warfarin	0.93	0.0744	RE-LY, Connolly et al, 200915
Rivaroxaban:warfarin	1.03	0.0736	ROCKET AF, Patel et al, 201117
Severity of Major Bleeds
Severity	Proportion	Standard Error	Source
Proportion of major bleeds that are:
Fatal	0.080	0.0232	Walraven et al, 200258
Occurrence of Minor Bleeds Relative to Major Bleeds
	Relative Risk	Standard Error	Source
Minor bleed:major bleed	2.28	0.4552	De Caterina et al, 201057

Abbreviations: HAS-BLED, Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile international normalized ratios (INRs), Elderly, Drugs or alcohol; LAAC device, left atrial appendage closure device with delivery system.

^aStandard deviation assumed same as HAS-BLED score of one.